Furthermore, it has been proposed that podoplanin might serve as a potential clinical marker for the malignant progression of oral leukoplakia [62], and it is regarded as a novel myoepithelial marker in salivary gland tumors [63]. This evidence concerns the gene PDPN and Oral leukoplakia.